Skip to main content
Erschienen in: Medical Oncology 4/2011

01.12.2011 | Original Paper

Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival

verfasst von: Chunxia Su, Caicun Zhou, Songwen Zhou, Jianfang Xu

Erschienen in: Medical Oncology | Ausgabe 4/2011

Einloggen, um Zugang zu erhalten

Abstract

To investigate whether expression of several cytokines affected clinical outcome in non-small cell lung cancer patients. A total of 86 stage IIIB/IV non-small cell lung cancer patients, treated with platinum-based doublets, were examined expression levels of IL-1, IL-2R, IL-5, IL-6, IFN-γ, TNF-α pre- and post-chemotherapy. Enzyme-linked immunosorbent assay technique was performed. Kaplan–Meier analysis and Cox regression analyses were used to adjust for possible confounding variables. IL-6 expression levels were significantly decreased due to chemotherapy in patients with stable disease (P = 0.041). IL-2R expression levels were significantly increased due to chemotherapy in patients with progression disease (P = 0.010). Patients with high concentrations of TNF post-chemotherapy had a significantly longer survival (P = 0.009, 17 months versus 11 months) than low levels. Multivariate analysis showed that sex, response rate, IL-1 and TNF-α were significantly predictive of the survival. Serum IL-6 and IL-2R levels correlated with chemoresponse in advanced non-small cell lung cancer, serum IL-1 and TNF-α can be predictive factors in advanced non-small cell lung cancer.
Literatur
1.
Zurück zum Zitat Camps C, Sirera R, Iranzo V, Tarón M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer. 2007;8(6):369–75.PubMedCrossRef Camps C, Sirera R, Iranzo V, Tarón M, Rosell R. Gene expression and polymorphisms of DNA repair enzymes: cancer susceptibility and response to chemotherapy. Clin Lung Cancer. 2007;8(6):369–75.PubMedCrossRef
2.
Zurück zum Zitat Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, GELCAPS Consortium, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16:2333–40.PubMedCrossRef Matakidou A, el Galta R, Webb EL, Rudd MF, Bridle H, GELCAPS Consortium, et al. Genetic variation in the DNA repair genes is predictive of outcome in lung cancer. Hum Mol Genet. 2007;16:2333–40.PubMedCrossRef
3.
Zurück zum Zitat Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;1;10(15):4939–43.CrossRef Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 2004;1;10(15):4939–43.CrossRef
4.
Zurück zum Zitat Derin D, Soydinç HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in non-small cell lung cancer. Lung Cancer. 2008;59(2):240–5.PubMedCrossRef Derin D, Soydinç HO, Guney N, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in non-small cell lung cancer. Lung Cancer. 2008;59(2):240–5.PubMedCrossRef
5.
Zurück zum Zitat Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005;23(3):193–200.PubMedCrossRef Dudek AZ, Mahaseth H. Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest. 2005;23(3):193–200.PubMedCrossRef
6.
Zurück zum Zitat Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 2006;24(5):492–6.PubMedCrossRef Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Serum vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8) levels in small cell lung cancer. Cancer Invest. 2006;24(5):492–6.PubMedCrossRef
7.
Zurück zum Zitat Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages ii and iii gastric carcinoma. Clin Cancer Res. 2008;15;14(2):428–34.CrossRef Liao WC, Lin JT, Wu CY, Huang SP, Lin MT, Wu AS, et al. Serum interleukin-6 level but not genotype predicts survival after resection in stages ii and iii gastric carcinoma. Clin Cancer Res. 2008;15;14(2):428–34.CrossRef
8.
Zurück zum Zitat Naumnik W, Chyczewska E, Kovalchuk O, Tałałaj J, Izycki T, Panek B. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst. 2004;49:246–51.PubMed Naumnik W, Chyczewska E, Kovalchuk O, Tałałaj J, Izycki T, Panek B. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer. Rocz Akad Med Bialymst. 2004;49:246–51.PubMed
9.
Zurück zum Zitat Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;5:1087–100. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res. 1998;5:1087–100.
10.
Zurück zum Zitat Rudd RM, Gower NH, James LE, Gregory W, Eisen T, Lee S, et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:292a. Rudd RM, Gower NH, James LE, Gregory W, Eisen T, Lee S, et al. Phase III randomized comparison of gemcitabine and carboplatin (GC) with mitomycin, ifosfamide and cisplatin (MIP) in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol. 2002;21:292a.
11.
Zurück zum Zitat Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20:4285–91.PubMedCrossRef Scagliotti GV, De Marinis F, Rinaldi M, Crino L, Gridelli C, Ricci S, et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J Clin Oncol. 2002;20:4285–91.PubMedCrossRef
12.
Zurück zum Zitat Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, et al. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non–small-cell lung cancer. Clinical Lung Cancer. 2008;9(Suppl. 2):S76–82.PubMedCrossRef Rosell R, Manegold C, Moran T, Garrido P, Blanco R, Lianes P, et al. Can we customize chemotherapy? Individualizing cytotoxic regimens in advanced non–small-cell lung cancer. Clinical Lung Cancer. 2008;9(Suppl. 2):S76–82.PubMedCrossRef
13.
Zurück zum Zitat Łukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117(5–6):247–51.PubMed Łukaszewicz M, Mroczko B, Szmitkowski M. Clinical significance of interleukin-6 (IL-6) as a prognostic factor of cancer disease. Pol Arch Med Wewn. 2007;117(5–6):247–51.PubMed
14.
Zurück zum Zitat Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003;18;100(6):3410–5.CrossRef Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, et al. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003;18;100(6):3410–5.CrossRef
15.
Zurück zum Zitat Siemińska A. The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients. Pol Merkur Lekarski. 2004;16(92):188–90.PubMed Siemińska A. The value of measuring the serum level of soluble interleukin-2 receptors in lung cancer patients. Pol Merkur Lekarski. 2004;16(92):188–90.PubMed
16.
Zurück zum Zitat Song LH, Song XR, Liu MQ, Zhang XQ, Zheng L, Li XJ, et al. Prognostic factors in patients with stage III and IV non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2004;26(6):345–8.PubMed Song LH, Song XR, Liu MQ, Zhang XQ, Zheng L, Li XJ, et al. Prognostic factors in patients with stage III and IV non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2004;26(6):345–8.PubMed
Metadaten
Titel
Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival
verfasst von
Chunxia Su
Caicun Zhou
Songwen Zhou
Jianfang Xu
Publikationsdatum
01.12.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 4/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9645-6

Weitere Artikel der Ausgabe 4/2011

Medical Oncology 4/2011 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.